KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Inventory (2021 - 2025)

Novavax (NVAX) has 6 years of Inventory data on record, last reported at $13.5 million in Q3 2025.

  • For Q3 2025, Inventory rose 56.41% year-over-year to $13.5 million; the TTM value through Sep 2025 reached $13.5 million, up 56.41%, while the annual FY2024 figure was $8.7 million, 79.02% down from the prior year.
  • Inventory reached $13.5 million in Q3 2025 per NVAX's latest filing, up from $10.2 million in the prior quarter.
  • Across five years, Inventory topped out at $256.3 million in Q2 2022 and bottomed at $8.6 million in Q3 2024.
  • Average Inventory over 5 years is $46.0 million, with a median of $19.6 million recorded in 2023.
  • Peak YoY movement for Inventory: tumbled 94.83% in 2021, then surged 313.47% in 2022.
  • A 5-year view of Inventory shows it stood at $8.9 million in 2021, then surged by 313.47% to $36.7 million in 2022, then increased by 13.67% to $41.7 million in 2023, then crashed by 79.02% to $8.7 million in 2024, then skyrocketed by 54.43% to $13.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $13.5 million in Q3 2025, $10.2 million in Q2 2025, and $10.3 million in Q1 2025.